This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Singh AK et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098
US Food and Drug Administration (online 9 March 2007) Public Health Advisory: erythropoiesis-stimulating agents (ESAs) [http://www.fda.gov/cder/drug/advisory/RHE2007.htm] (accessed 23 April 2007)
Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590
Drueke TB et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084
Phrommintikul A et al. (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381–388
Strippoli GF et al. (2007) Haemoglobin targets: we were wrong, time to move on. Lancet 369: 346–350
Levin A (2007) Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 22: 309–312
Collins AJ et al. (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465–2473
Collins AJ et al. (2000) Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345–349
Regidor DL et al. (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181–1191
Mix TC et al. (2005) Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149: 408–413
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Dr Singh reports having received consulting fees from Abbott, Amgen, Horizon Blue Cross Blue Shield, Merck (Germany), Ortho Biotech Clinical Affairs, Roche and Watson, and lecture fees from Abbott, Amgen, Genzyme, Ortho Biotech Clinical Affairs, Pfizer, Roche, Scios and Watson; having served on advisory boards for Advanced Magnetics, Amgen, Ortho Biotech Clinical Affairs, Roche and Watson; and having received grant support from Amgen, Baxter, Dialysis Clinic, Genentech, the National Institutes of Health, Ortho Biotech Clinical Affairs, Roche and Watson.
Rights and permissions
About this article
Cite this article
Singh, A. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Rev Nephrol 3, 406–407 (2007). https://doi.org/10.1038/ncpneph0539
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0539